| Literature DB >> 28867926 |
Hao Chen1, Juan He2, Raymond Lanzafame3, Istvan Stadler4, Hamid El Hamidi5, Hui Liu5, Jonathan Celli5, Michael R Hamblin6, Yingying Huang6, Emily Oakley7, Gal Shafirstein7, Ho-Kyoon Chung8, Shin-Tson Wu2, Yajie Dong9.
Abstract
While OLEDs have struggled to find a niche lighting application that can fully take advantage of their unique form factors as thin, flexible, lightweight and uniformly large-area luminaire, photomedical researchers have been in search of low-cost, effective illumination devices with such form factors that could facilitate widespread clinical applications of photodynamic therapy (PDT) or photobiomodulation (PBM). Although existing OLEDs with either fluorescent or phosphorescent emitters cannot achieve the required high power density at the right wavelength windows for photomedicine, the recently developed ultrabright and efficient deep red quantum dot light emitting devices (QLEDs) can nicely fit into this niche. Here, we report for the first time the in-vitro study to demonstrate that this QLED-based photomedical approach could increase cell metabolism over control systems for PBM and kill cancerous cells efficiently for PDT. The perspective of developing wavelength-specific, flexible QLEDs for two critical photomedical fields (wound repair and cancer treatment) will be presented with their potential impacts summarized. The work promises to generate flexible QLED-based light sources that could enable the widespread use and clinical acceptance of photomedical strategies including PDT and PBM.Entities:
Keywords: photobiomodulation; photodynamic therapy; photomedicine; quantum dot light emitting devices (QLEDs)
Year: 2017 PMID: 28867926 PMCID: PMC5576728 DOI: 10.1002/jsid.543
Source DB: PubMed Journal: J Soc Inf Disp ISSN: 1071-0922 Impact factor: 2.140